Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials

Journal of Human Hypertension volume 29, pages 473–477 (2015)Cite this article

Subjects

Abstract

In studies of antihypertensive therapy, relative cardiovascular (CV) risk reduction is largely independent of attained systolic blood pressure (SBP). How this translates to absolute risk reduction (ARR) in diabetes is not clear. We have compared 5-year CV outcomes in 10 studies of intensive versus moderate or active versus placebo therapy in subjects with type 2 diabetes and attained SBP⩾140 mm Hg. Attained SBP⩾140 mm Hg occurred in five early studies (HOT n=1001, UKPDS n=1148, SHEP n=583, SYSTEUR n=422, MICRO_HOPE n=3377) and attained SBP<140 mm Hg occurred in five recent studies (ABCD-NT n=480, ADVANCE n=11,140 INVEST n=4266, ACCORD n=4733, ROADMAP n=4447). In each study, ARR was calculated from group mean data and expressed as % change in CV events over 5 years per 10 mm Hg decrease in attained SBP. In studies with attained SBP⩾140 mm Hg, ARR was 13±2.6% per 10 mm Hg, and the number needed to treat (NNT) to prevent one event in 5 years was 8. In studies with attained SBP<140 mm Hg, ARR was 1.6±1.9% per 10 mm Hg (P=0.0007), and NNT was 68. The present analysis indicates that CV outcomes reach a plateau after attaining SBP of 140 mm Hg in patients with type 2 diabetes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335: 765–774.

    Article  CAS  Google Scholar 

  2. MacMahon S . Blood pressure reduction and the prevention of stroke. J Hypertens Suppl 1991; 9: S7–S10.

    Article  CAS  Google Scholar 

  3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

    Article  Google Scholar 

  4. Nilsson PM, Cederholm J . Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care 2011; 34: S109–S113.

    Article  Google Scholar 

  5. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–1419.

    Article  Google Scholar 

  6. Law MR, Morris JK, Wald NJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

    Article  CAS  Google Scholar 

  7. Kottke TE, Stroebel RJ, Hoffman RS . JNC 7—it's more than high blood pressure. JAMA 2003; 289: 2573–2575.

    Article  Google Scholar 

  8. Whitworth JA . 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.

    Article  Google Scholar 

  9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751–1762.

    Article  CAS  Google Scholar 

  10. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886–1892.

    Article  CAS  Google Scholar 

  11. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–684.

    Article  CAS  Google Scholar 

  12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–259.

  13. Schrier RW, Estacio RO, Esler A, Mehler P . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–1097.

    Article  Google Scholar 

  14. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840.

    Article  CAS  Google Scholar 

  15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.

    Article  CAS  Google Scholar 

  16. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–713.

    Article  Google Scholar 

  17. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–68.

    Article  CAS  Google Scholar 

  18. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575–1585.

    Article  Google Scholar 

  19. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–917.

    Article  CAS  Google Scholar 

  20. Collins R, MacMahon S . Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–298.

    Article  CAS  Google Scholar 

  21. Arguedas JA, Perez MI, Wright JM . Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009, CD004349.

  22. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29: 4–16.

    Article  CAS  Google Scholar 

  23. Bangalore S, Kumar S, Lobach I, Messerli FH . Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799–2810, 9 p following 810.

    Article  CAS  Google Scholar 

  24. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P . Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011; 29: 1253–1269.

    Article  CAS  Google Scholar 

  25. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012; 172: 1296–1303.

    Article  Google Scholar 

  26. Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J et al. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care 2013; 36: 3287–3296.

    Article  Google Scholar 

  27. Clinical Practice Guidelines Diabetes Care 2013; 36 (Suppl): S1–S2.

  28. Mancia G, Fagard R, Narkiewicz R, Redán J, Zanchetti A, Böhm M et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925–1938.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Centre, Austin Health & University of Melbourne, Heidelberg West, Victoria, Australia

    G Jerums, S Panagiotopoulos & E Ekinci

  2. Department of Endocrinology & Diabetes, St Vincents Hospital & University of Melbourne, Fitzroy, Victoria, Australia

    R J MacIsaac

Authors
  1. G Jerums
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Panagiotopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Ekinci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R J MacIsaac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Jerums.

Ethics declarations

Competing interests

R. MacIsaac has received lecture fees and/or travel grants from Lilly. E. Ekinci has received travels grants from Sanofi and Lilly. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jerums, G., Panagiotopoulos, S., Ekinci, E. et al. Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. J Hum Hypertens 29, 473–477 (2015). https://doi.org/10.1038/jhh.2014.117

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2014.117

This article is cited by

Search

Advanced search

Quick links